Peripheral blood mononuclear cells were separated from whole blood by Ficoll-Paque density gradient centrifugation according manufacturer's instructions (GE Healthcare).
RNAi MAX (Invitrogen). 8 biological-replicates samples for RNA analysis were harvested at 24-hours post-transfection.
Purification of total RNA from transfected and stimulated THP-1 cells.
For gene expression validation in THP-1 cells, total RNA was purified using PureLink® RNA Mini Kit (Ambion™, Life Technologies) combined with an on-column DNase treatment according to the manufacturer's instructions using lysis buffer added 1%β-mercaptoethanol and a final elution volume of 30 ul.
qPCR analysis of gene expression in monocytes and THP-1 cells
For validation of gene expression in monocytes and THP-1 cells, cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen) with a total input RNA of 200 ng for monocytes and 436 ng for THP-1 cells in a 20 µl reaction volume. All samples were run in triplicates in a 5 µl reaction volume consisting of 0.22 µl cDNA, 1.5 µl of primer mix (1.67 pmol/µl), 0.78 µl RNase-free water, and 2.5 µl Brilliant SYBR Green QPCR Master Mix (Invitrogen). PCR reactions were quantified using the QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). The thermal cycler details were as follows: 10 min at 95°C followed by amplification of the cDNA for 40 cycles with melting for 30 s at 95°C, annealing for 1 min at 60°C, and elongation for 45 s at 72°C.
qPCR data analysis of gene expression
The standard deviation (SD) between triplicates in qPCR experiments from both monocytes and THP-1 cells was required to be no more than 0.6. If the SD of triplicates exceeded 0.6, pairwise replicates were examined using the same threshold and the pairs with the minimum SD were kept for further processes. The samples that did not satisfy these criteria in triplicates or in any of the replicate pairs were eliminated from the analyses. For the qPCR validation focusing on MDP responses using paired samples, only the samples satisfy these criteria in both 'before MDP' and 'after MDP' states were shown in the resulting plots. All results were normalized to human RPLP0 (ribosomal protein large p0) by the 2 -ΔCt method 1 . In order to eliminate batch differences between the two rounds of miR-155 experiments in monocytes using MDP stimuli ( Figure 4A , right panel) and using LPS/E.coli stimuli ( Figure 4B ), for each unstimulated CD WT and CD NOD2 subjects used in both experiments (5 for CD WT and 4 for CD NOD2 subjects, for details see Supplementary   Table 1) , we calculated the qPCR-expression differences between experiments as
per subject and the median !"#$! per subject groups was used for multiplying to the qPCR expression values derived from the later LPS/E.coli experiment.
qPCR analysis of miRNA expression in monocytes
For validation of miRNA expression, total RNA (10 ng) was reverse transcribed into cDNA using miRNA-specific primers (Applied Biosystems) and the TaqMan® miRNA reverse transcription kit (Applied Biosystems) according to the manufacturer's instructions. The expression levels of selected miRNAs were measured using commercially available predesigned miRNA-specific TaqMan® miRNA assays (Applied Biosystems) according to the manufacturer's recommendations. PCR reactions were quantified using the LightCycler 480 real-time PCR system (Roche). All samples were run in triplicates in a 5 µl reaction volume and cycles were run as previously described by Coskun et al. 2 . The same SD threshold 0.6 as used in gene qPCR analysis was employed for examining technical triplicates or replicate pairs. Expression levels of each miRNA were normalized to human RNU6B (RNA, U6B small nuclear). The relative expression levels of these miRNAs were determined by the 2 -ΔCt method 2 .
Mapping and Quantification of RNA-seq libraries
After filtering the reads for a minimum sequencing quality of 30 in 50% of the bases with the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), nucleotides with quality score lower than 20 were subsequently trimmed from 3'end of the RNA-seq reads. The remaining reads were mapped to the hg19 genome assembly using Tophat v2.0. 
Mapping and Quantification of Small RNA-Seq
After truncating the 3'-ends adaptors and filtering the reads for a minimum sequencing quality of 30 in 50% of the bases with the FASTX-Toolkit, we used Bowtie v0.12.7 6 (settings: --strata --best -k 10 -3 30) to map small RNA-Seq to the hg19 reference assembly. Because the protocol applied did not distinguish strands, miRNA levels were quantified by the sum of mapped reads falling into the corresponding genomic coordinates of their precursors using UCSC gene annotation, regardless of strand. The lowest 40%
expressed miRNAs (including miRNAs with no expression) were removed before running differential analysis in DESeq. The expression of miRNAs was visualized as TPM (tags per million mapped tags).
Association Between miRNAs and Their Potential Target Genes
We only analyzed miRNA-gene interactions supported by the published data in mirTarBase4.3 7 . We required miRNA and gene expression from each interaction to be reversely regulated in any of the differential expression pairs consisting of miRNAs and genes passing the cutoff from differential expression analysis (FDR ≤ 0.05) (arrows in Figure 1 ).
Gene Ontology Analysis and KEGG pathway analysis
GO analysis was performed using DAVID 8,9 using all expressed genes in all samples as background. GO terms (BP_FAT, CC_FAT and MF_FAT) were sorted by corresponding
Bonferroni-adjusted P values. Gene enrichment analysis in KEGG 10 pathways was conducted using Pathview 11 using native KEGG graphs and default settings.
Pseudo counts and outlier truncation
For each analysis involving the use of log transformation when zero values existed in the analyzed dataset, the smallest non-zero value in the analyzed data points was employed as pseudo-count before log transformation. For the ease of visualization, in Figure 4F Primer pairs used for gene expression validation.
Supplementary Table 3:
List of differentially expressed genes and miRNAs for respective group-wise analysis KCNMA1  GJB2  CXCL13  MIR210HG  OLFM4  CCL22  RGS1  DUSP5  IFI6  IFITM3  FTLP2  CAMP  RN7SL2 t a r g e t g e n e s in S N P validated miR155 target genes in SNP subjects miR155 in SNP subjects
